Arcutis Biotherapeutics Inc (ARQT) Stock Analysis
Verdict: BUY
Explosive 95% revenue growth and 90% gross margins signal a 2025 profitability pivot, though thin cash reserves remain the primary risk.
Investment score: 68/100
Analysis as of
Is Arcutis Biotherapeutics Inc stock worth reviewing? AI model thesis
The AI model rates ARQT as a BUY based on its transition to a profitable commercial entity, supported by 90%+ gross margins and a robust pipeline. The model views the 27.4% upside to consensus $34 targets as achievable if the 2025 operating income target of -12M is met.
7-factor investment score
- Valuation: 60/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 80/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Arcutis Biotherapeutics Inc opportunities and risks
What speaks for ARQT
- Operating Leverage Pivot
What speaks against ARQT
- Cash Runway & Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ARQT | n/a | 8.0x | 220.7x | 90.9% | -0.6% | 0.8% |
| BEAM | n/a | 21.3x | n/a | -32.4% | -39.7% | -11.0% |
| IDYA | n/a | 15.3x | n/a | 29.7% | -62.2% | -2.5% |
| VKTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.9% |
| DYN | n/a | 0.0x | n/a | 0.0% | 0.0% | -13.6% |
| RARE | n/a | 4.3x | n/a | 83.6% | -91.0% | -16.9% |
| Peer median | n/a | 4.3x | n/a | 0.0% | -39.7% | -11.0% |
Frequently asked questions about Arcutis Biotherapeutics Inc (ARQT)
Is ARQT stock a good investment?
The cached TradeMates AI model rates Arcutis Biotherapeutics Inc as BUY with an investment score of 68/100. The AI model rates ARQT as a BUY based on its transition to a profitable commercial entity, supported by 90%+ gross margins and a robust pipeline. The model views the 27.4% upside to consensus $34 targets as achievable if the 2025 operating income target of -12M is met. This is algorithmic model output, not personal investment advice.
Is ARQT stock a buy?
The TradeMates model verdict for ARQT is BUY with an investment score of 68/100. Treat this as a model signal to review, not a personal buy recommendation.